UNSPSC 51312400: Antihistamine or H1 blocker ethylenediamines

Antihistamine or H1 blocker drugs made from an ethylamine, C2H4(NH2)2.

UNSPSC 51312400 Antihistamine or H1 blocker ethylenediamines is a Class code, but the recent state and local opportunities tagged under it do not align with this narrowly defined pharmaceutical ingredient. Instead, the code shows activity centered on broader pharmaceutical procurement — generic multi-source drugs, over-the-counter products, naloxone, and direct-to-manufacturer prescription programs. State and local buyers under this code include county health departments, state health and human services agencies, and cooperative purchasing alliances serving multiple jurisdictions. The work involves sourcing pharmaceutical inventory for community health initiatives, establishing manufacturer relationships to manage pharmacy benefit costs, and supplying emergency response medications like naloxone through competitive bidding and cooperative agreements.

Recent activity appears concentrated in Florida and Minnesota, with Texas initiating exploratory procurement for pharmacy benefit innovation. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023 (note: the due date predates the posting date, indicating a data error in the source). The Minnesota Department of Administration's Office of State Procurement, administering the Multistate Cooperative Purchasing Alliance (MMCAP), released RFP S1070000015802 on January 20, 2026, to establish multiple contracts for generic pharmaceuticals and OTC products distributed across participating state and local facilities, with proposals due March 26, 2026 and contract awards effective July 1, 2026. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capability information for a proposed direct-to-manufacturer prescription program. These solicitations show state and local governments actively consolidating pharmaceutical procurement through both individual county contracts and multi-state cooperative purchasing vehicles.